Pharmafile Logo
Pharmafocus logo
Advanced Search

otezla

Showing 12 posts of 12 posts found.

celgene_building

Celgene’s Otezla becomes first and only FDA-approved therapy for oral ulcers in Behçet’s Disease

July 22, 2019
Sales and Marketing Behçet's disease, Behçet’s Disease, Celgene, apremilast, otezla, pharma

Celgene has revealed the US approval of Otezla (apremilast), confirming that the FDA awarded marketing authorisation for the treatment of …

News
bms_nassau_park_new_jersey

Bristol-Myers Squibb to sell off Celgene’s Otezla ahead of $74 billion merger

June 24, 2019
Manufacturing and Production Bristol-Myers Squibb, Celgene, FTC, otezla, pharma, psoriasis

Bristol-Myers Squibb has agreed to sell off Celgene’s psoriasis treatment Otezla, to appease antitrust regulators. BMS will divest one of …

News
celgene_1_02

Celgene’s Otezla produces “meaningful benefits” beyond traditional metrics in plaque psoriasis

September 13, 2018
Research and Development Celgene, otezla, pharma, psoriasis

Celgene made its voice heard amongst the chorus of new psoriasis data emerging from the European Academy of Dermatology and …

News
celgene_1_02

Celgene showcases strong Otezla data in psoriatic arthritis

June 13, 2018
Research and Development Celgene, EULAR, otezla, pharma

Celgene has seized the opportunity at the Annual European Congress of Rheumatology in Amsterdam to reveal positive new data for …

News
celgene_1_02

Celgene reveals strong P3 Otezla data in rare inflammatory condition

February 19, 2018
Research and Development, Sales and Marketing Behçet's disease, Celgene, apremilast, otezla, pharma

Celgene has lifted the curtain on strong new Phase 3 data for its phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 18, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten

While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …

News
celgene_1_02

Celgene’s Otezla hits primary endpoint in psoriatic arthritis study

November 15, 2016
Manufacturing and Production, Research and Development Celgene, otezla, psoriatic arthritis

Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment …

News
celgene_1_02

Celgene’s Otezla approved by NICE for chronic plaque psoriasis

October 20, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, NICE, apremilast, otezla

NICE has given its approval to another indication for Celgene’s Otezla (apremilast), meaning NHS patients now have access to the …

News

NICE backs Celgene’s Otezla for psoriatic arthritis

October 12, 2016
Research and Development, Sales and Marketing Celgene, NICE, otezla

The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …

News

New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs

December 16, 2015
Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin

NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …

News
Celgene image

NICE rejects Otelza but SMC recommends it

June 11, 2015
Sales and Marketing Astellas, Celgene, NHS, NICE, SMC, Xtandi, otezla

Draft guidance issued by NICE has seen rejections for products including Celgene’s Otelza and Astellas Pharma’s Xtandi, and a call …

News

Pfizer, Novartis and Celgene among late-stage psoriasis trial advances

March 23, 2015
Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib

Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024